Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 09, 2026 |
| Travere Therapeutics, Inc.RTRX · Entity 1562 | Director | May 08, 2019 | May 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,622 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 42,622 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Travere Therapeutics, Inc.
Report date May 08, 2019 · Filed May 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,000 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Grant · Acquired 2,000 · Balance 29,000 |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2029-05-07 | Direct | 8,000 |
Reported balance
After 2019-05-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-08 · Grant · Acquired 8,000 · Balance 8,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2018 Filed May 12, 2018 01:09 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029722 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 20:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,500 | $160.43 | $401,062.50 |
DisclosureSEC source: 0000886163-18-000050 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,649 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.70 to $163.35, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,500 | $145.00 | $362,500.00 |
DisclosureSEC source: 0000886163-18-000002 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,149 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:14 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,000 | $141.71 | $708,550.00 |
DisclosureSEC source: 0000886163-17-000138 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,649 F1 · kind: The reporting person contributed LGND common stock to an exchange fund in exchange for shares of the exchange fund. The LGND common stock was valued at $141.71 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed LGND common stock to an exchange fund in exchange for shares of the exchange fund. The LGND common stock was valued at $141.71 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,456 | $113.50 Strike: $113.50 | $278,756.00 |
DisclosureSEC source: 0000886163-17-000072 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456 Underlying: Common Stock · 2,456 shares Expires 2027-05-25 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:16 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000072 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,649 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017 Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:20 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033725 · doc4.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:20 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033725 · doc4.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 20:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,000 | $115.00 | $115,000.00 |
DisclosureSEC source: 0000886163-16-000223 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,983 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $106.87 | $21,373.00 |
DisclosureSEC source: 0000886163-16-000217 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,317 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.85 to $106.88, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 866 | $105.82 | $91,642.80 |
DisclosureSEC source: 0000886163-16-000217 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,517 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.41 to $106.37, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 400 | $104.66 | $41,863.00 |
DisclosureSEC source: 0000886163-16-000217 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,383 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.29 to $105.17, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 22:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $103.59 | $20,718.00 |
DisclosureSEC source: 0000886163-16-000217 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,783 F1 · shares: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.22 to $103.96, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2016 Filed Sep 9, 2016 20:05 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,666 | $0.00 Strike: $45.60 | $0.00 |
DisclosureSEC source: 0000886163-16-000222 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,666 shares Expires 2016-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to report the exercise of options prior to the previously reported open market sales on September 01, 2016. F2 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. Read SEC document |
| September 01, 2016 Filed Sep 9, 2016 20:05 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,666 | $45.60 | $75,969.60 |
DisclosureSEC source: 0000886163-16-000222 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to report the exercise of options prior to the previously reported open market sales on September 01, 2016. F2 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.